Get informed when a big investor buys or sells
+ Follow-2.25%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 300294.SZ is -2.25%. That is below the Healthcare sector average of 13.1%. Investors often review this figure alongside China Resources Boya Bio-pharmaceutical Group , Ltd.'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, 300294.SZ currently prints -2.25% for ROE, while the sector average sits near 13.1%. That is roughly 117.2% below the sector mean. Large gaps often invite a closer look at China Resources Boya Bio-pharmaceutical Group , Ltd.'s growth, margins, and balance sheet.
Return on Equity shows how effectively China Resources Boya Bio-pharmaceutical Group , Ltd. converts resources into returns. At -2.25%, 300294.SZ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 300294.SZ's ROE (-2.25%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack China Resources Boya Bio-pharmaceutical Group , Ltd.'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.